Alpha Tau Medical (DRTS) Stock News

Alpha Tau (Nasdaq: DRTS) reported completion of patient enrollment in its multicenter IMPACT pilot study evaluating intratumoral Alpha DaRT® plus first-line chemotherapy for newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. Enrollment was expanded three times, from 12 to 48 patients, following strong interest from patients and clinicians.

Alpha DaRT is administered once alongside standard first-line regimens (mFOLFIRINOX or gemcitabine + nab-paclitaxel), an approach supported by a favorable safety profile from earlier Israeli and Canadian studies. According to Alpha Tau, initial IMPACT data are targeted for early 2027 to inform a planned pivotal study and support its broader global pancreatic cancer program, including the ACAPELLA trial in France and a study at the University of Verona.

Nano Dimension (Nasdaq: NNDM) appointed Nadav Kidron to its Board of Directors and plans to form a new Strategy and Capital Allocation Committee as part of an ongoing strategic review led by Chairman Phillip Borenstein.

Kidron, President and CEO of Oramed Pharmaceuticals (Nasdaq: ORMP) and a director at Alpha Tau Medical (Nasdaq: DRTS) and Lifeward (Nasdaq: LFWD), will chair the committee. According to Nano Dimension, the committee will help evaluate capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets and other strategic opportunities aimed at maximizing long-term shareholder value.

Alpha Tau (NASDAQ: DRTS) reported second quarter 2026 results and a major corporate update, highlighting rapid clinical and commercial progress for its Alpha DaRT cancer therapy. The company entered a 20‑year U.S. prostate cancer collaboration with Tolmar, including a $20 million equity investment at a 25% premium, $15 million for a new U.S. manufacturing facility, and up to $161.5 million in potential milestones, plus future supply at 60% of net sales.

Key clinical updates included 100% local disease control and 67% complete response in the U.S. REGAIN recurrent glioblastoma trial, full enrollment of the 88‑patient ReSTART pivotal cSCC study, strong pancreatic cancer survival data, and a 100% objective response rate with 18.2‑month median overall survival in a head and neck cancer combination study. Cash and deposits rose to $104.8 million, while the six‑month net loss widened to $68.8 million due largely to non‑cash warrant remeasurement.

Alpha Tau (Nasdaq: DRTS) plans to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE), alongside Nasdaq. According to Alpha Tau, it has filed to register 92,478,154 outstanding shares plus various potential future shares from convertible securities, option pools and its employee share purchase plan. The shares are expected to trade on TASE under the English symbol DRTS and the Hebrew symbol דרטס.

Alpha Tau (Nasdaq: DRTS) reported clinical data for Alpha DaRT® combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In a single-center, open-label study, 9 evaluable patients achieved a 100% systemic objective response rate, with 4 complete and 5 partial responses.

According to Alpha Tau, median overall survival reached 18.2 months and median progression-free survival 5.4 months, compared with historical pembrolizumab monotherapy benchmarks of 12.3 and ~3.2 months. No Alpha DaRT-related serious adverse events were seen; only two Grade 1 events occurred. The Simon two-stage design’s success threshold (more than six responders) was surpassed, recruitment was completed at 11 patients, and the company is discussing a larger U.S. study with the FDA. Alpha Tau cautions against direct comparisons with unrelated trials.

Alpha Tau (Nasdaq: DRTS) reported the first successful treatment of an immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) in its ADMIRE clinical study, evaluating intratumoral Alpha DaRT therapy for this high‑risk group. The procedure was performed at Banner MD Anderson Cancer Center in Gilbert, Arizona, by Dr. Michael Samuels and Dr. Thomas Shellenberger.

ADMIRE targets immunocompromised patients, including organ transplant recipients, those with hematologic malignancies or on chronic immunosuppressive therapy, who face up to a 65–100‑fold higher cSCC incidence and limited treatment options. The trial builds on experience from Alpha Tau’s ReSTART pivotal study for recurrent cSCC, which recently completed enrollment.

Oramed (NASDAQ: ORMP) released a shareholder letter detailing portfolio gains, Scilex loan repayments, and upcoming Russell 2000/3000 index inclusion.

Key points include Alpha Tau's value rising to about $167M, Scilex repayments totaling roughly $118M to date, and total cash and assets of about $270M as of March 31, 2026 (unaudited).

Alpha Tau (Nasdaq: DRTS) reported the first recurrent glioblastoma patient treated with Alpha DaRT outside the US, and first in Israel, at Hadassah University Medical Center. Using a proprietary brain applicator and stereotactic neuro-navigation, sources were implanted via a single minimally invasive burr hole, with the procedure completed safely and without unexpected complications. The case was performed under the ALL broad-access protocol and complements Alpha Tau’s multicenter US REGAIN trial, which recently received FDA clearance to proceed to full enrollment with two additional US academic centers.

Alpha Tau (Nasdaq:DRTS) received FDA clearance to complete enrollment of the final seven patients in its U.S. REGAIN recurrent glioblastoma trial and to add two new U.S. academic cancer centers as sites.

Early interim data from the first three patients showed 100% local disease control, a 67% complete response rate and one grade 3 serious adverse event, which resolved.

The FDA had previously granted Breakthrough Device designation and accepted Alpha Tau into its TPLC TAP Pilot for Alpha DaRT.